Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

209.23
-10.5300-4.79%
Volume:4.21M
Turnover:888.79M
Market Cap:369.79B
PE:88.66
High:219.00
Open:218.60
Low:208.75
Close:219.76
52wk High:244.81
52wk Low:164.39
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.07
T/O Rate:0.24%
Dividend:6.65
Dividend Rate:3.18%
EPS(TTM):2.36
EPS(LYR):2.36
ROE:6225.00%
ROA:9.81%
PB:-113.09
PE(LYR):88.66

Loading ...

Abbvie Exec Says Have Plenty of Firepower to Pursue Both Early and Late Stage M&a Opportunities - Conf Call

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Potential Deals Not Limited to Early Stage, and Focused on Core Areas, Immunology, Neuroscience, Oncology and Building Out Obesity

THOMSON REUTERS
·
Feb 04

AbbVie says ‘plenty of capacity’ to invest in internal and external innovation

TIPRANKS
·
Feb 04

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

TIPRANKS
·
Feb 04

Stock Track | AbbVie Plunges 7.25% Intraday Despite Earnings Beat on Concerns Over Revenue Quality and Portfolio Weaknesses

Stock Track
·
Feb 04

Abbvie Shares Down 7.5% After Q4 Results

THOMSON REUTERS
·
Feb 04

Stock Track | AbbVie Plunges 6.5% in Pre-market Despite Earnings Beat as Revenue Quality Concerns and Portfolio Weaknesses Emerge

Stock Track
·
Feb 04

BUZZ-U.S. STOCKS ON THE MOVE-Bio-Techne, AbbVie, Johnson Controls

Reuters
·
Feb 04

Is AbbVie (ABBV) Still Attractive After Mixed Returns And Discounted Cash Flow Signal?

Simply Wall St.
·
Feb 04

AbbVie says entering 2026 with ‘substantial momentum’

TIPRANKS
·
Feb 04

AbbVie sees FY26 revenue growth of 9.5%

TIPRANKS
·
Feb 04

Abbvie Anticipates First-Quarter Net Revenues of Approximately $14.7 Billion

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Co Anticipates Total Sales Growth of 9.5% in 2026

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Co Is Well Positioned to Deliver High Single Digit Revenue Growth Through 2029- Conf Call

THOMSON REUTERS
·
Feb 04

Abbvie Expects 2026 Aesthetics Sales of $5 Billion Including Botox Cosmetic Revenue of $2.7 Billion

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Expect 2026 Skyrizi Revenue of $21.5 Billion Driven and Rinvoq Revenue of $10.1 Billion

THOMSON REUTERS
·
Feb 04

Abbvie Expects First-Quarter Adjusted Earnings per Share Between $2.97 and $3.01

THOMSON REUTERS
·
Feb 04

Abbvie Exec Says Anticipate Aesthetics Growth Will Remain Challenged in 2026 and Focused on Investing to Stimulate the Market, Which Remains Highly Under Penetrated

THOMSON REUTERS
·
Feb 04

AbbVie's Q4 Earnings Beat Expectations as Botox Drives Rare Growth in Aesthetics Unit, Firm Raises Full-Year Profit Outlook

Stock News
·
Feb 04

AbbVie veröffentlicht Präsentation zum aktuellen Forschungs- und Entwicklungsstand der Pipeline

Reuters
·
Feb 04